Recommended treatment guideline for breast cancer. Finnish Breast Cancer Group
Rintasyöpäryhmä ry, S.
Duodecim; Laaketieteellinen Aikakauskirja 113(22): 2341-2348
1997
ISSN/ISBN: 0012-7183 PMID: 10892143 Document Number: 474690
Document emailed within 1 workday
Related Documents
Axelsson, C.K.; Andersen, J.A.; Andersen, K.W.; Blichert-Toft, M.; Dombernowsky, P.; Hansen, M.; Krag, C.; Mouridsen, H.T.; Overgaard, M.; Rasmussen, B.B. 1991: Prognosis after surgical treatment of breast cancer. 3. The low-risk group of the DBCG (Danish Breast Cancer Cooperative Group) Ugeskrift for Laeger 153(33): 2276-22792004: Adjuvant chemotherapy for early breast cancer: protocol and nonprotocol treatment options. Proceedings of a national research leader think tank and 3 regional breast cancer update working group meetings. July-October 2003 Oncology 18(4 Suppl. 1): 5-22
1974: Assessment of response to treatment in advanced breast cancer. British Breast Group Lancet 2(7871): 38-39
Lundin, A.C.; Söderkvist, P.; Eriksson, B.; Bergman-Jungeström, M.; Wingren, S. 1999: Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group Cancer Research 59(10): 2332-2334
Crivellari, D. 2002: Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group Tumori 88(1 Suppl. 1): S81-S82
Ansquer, Y.; Gautier, C.; Fourquet, A.; Asselain, B.; Stoppa-Lyonnet, D. 1998: Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group Lancet 352(9127): 541
Fortunato, L.; Drago, S.; Vitelli, C.E.; Santoni, M.; Gucciardo, G.; Cabassi, A.; Farina, M.; La Pinta, M.; Remedi, M.; Pagano, G.; Silipod, T.; Terribile, D.; Stagnitto, D.; Grassi, G.B. 2006: Sentinel lymph node biopsy in breast cancer. Experience of the Rome Breast Cancer Study Group Chirurgia Italiana 58(6): 689-696
Castiglione-Gertsch, M.; Tattersall, M.; Hacking, A.; Goldhirsch, A.; Gudgeon, A.; Gelber, R.D.; Lindtner, J.; Coates, A.; Collins, J.; Isley, M.; Senn, H.J.; Rudenstam, C.M. 1997: Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group European Journal of Cancer 33(14): 2321-2325
Nabholtz, J.M.; Lindsay, M.A.; Hugh, J.; Mackey, J.; Smylie, M.; Au, H.J.; Tonkin, K.; Allen, M. 1999: The academic global virtual concept in clinical cancer research and its application to breast cancer: The Breast Cancer International Research Group Seminars in Oncology 26(3 Suppl. 8): 4-8
Axelsson, C.K.; Mouridsen, H.T.; Zedeler, K. 1992: Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG) European Journal of Cancer 28a(8-9): 1415-1418
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Lipkus, I.M.; Iden, D.; Terrenoire, J.; Feaganes, J.R. 1999: Relationships among breast cancer concern, risk perceptions, and interest in genetic testing for breast cancer susceptibility among African-American women with and without a family history of breast cancer Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 8(6): 533-539
2006: Comparative effects of the administration period of adjuvant chemotherapy using doxifluridine (5'-DFUR) for 1 year versus 3 years after breast cancer surgery by the Shimane Breast Cancer Study Group Anticancer Research 26(1b): 591-597
Mitsuyama, S.; Kuroda, Y.; Ohsato, K.; Nakamura, Y.; Murakami, F.; Nishikata, F.; Ikeda, S.; Egami, T.; Mori, A.; Ohe, H. 1996: Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(9): 1153-1160
Struikmans, H.; Nortier, J.W.R.; Rutgers, E.J.Th.; Zonderland, H.M.; Bontenbal, M.; Elkhuizen, P.H.M.; van Tienhoven, G.; Tjan-Heijnen, V.C.G.; van Vegchel, T.; Tuut, M.K.; Benraadt, J. 2008: Guideline 'Treatment of breast cancer 2008' (revision) Nederlands Tijdschrift Voor Geneeskunde 152(46): 2507-2511
Taguchi, T.; Koyama, H.; Yayoi, K.; Wada, T.; Takatsuka, Y.; Sonoo, H.; Morimoto, K.; Tominaga, T.; Abe, R.; Enomoto, K. 1995: Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 495-508
Penault-Llorca, F.; Jacquemier, J.; Le Doussal, V.; Voigt, J.J. 1999: Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS) Annales de Pathologie 19(4): 280-282
Andersen, J.; Nielsen, M.; Christensen, L.; Ottesen, G.L.; Blichert-Toft, M. 1987: The significance of the frequency and occurrence of breast cancer for treatment. Essential aspects of new Danish studies of the natural history of breast cancer Acta Chirurgica Belgica 87(2): 103-107
1997: Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium Lancet 349(9064): 1505-1510
Thomsen, K. 1987: Changes in the therapy of operable breast cancer. Treatment of small breast cancer and preinvasive stages Fortschritte der Medizin 105(22): 425-428